CSPC Pharmaceutical’s SYS6020 Receives NMPA Approval for Myasthenia Gravis Clinical Trial
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Company
Eli Lilly’s Ebglyss Shows Positive Results in Phase III Study for Atopic Dermatitis Patients Previously Treated with Dupilumab
Eli Lilly & Co. (NYSE: LLY), a leading U.S. pharmaceutical company, has announced the results...
CANbridge Pharmaceuticals Scales Back US Operations, Focuses on China for R&D and Commercialization
CANbridge Pharmaceuticals Inc., (HKG: 1228), a China-based pharmaceutical company specializing in rare diseases, has announced...
Biogen’s Felzartamab Demonstrates Promising Results in Phase II Study for IgA Nephropathy
Biogen Inc. (NASDAQ: BIIB), a prominent biopharmaceutical company based in the U.S., has announced comprehensive...
Humanwell Healthcare Receives NMPA Approval for Chemically Synthesized Semaglutide Clinical Trial
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079), a leading healthcare company based in China, has...
RiboX Therapeutics’ Circular RNA Therapy RXRG001 Gets FDA Green Light for Dry Mouth Clinical Trial
RiboX Therapeutics, a Shanghai-based developer of circular RNA (circRNA) therapies, has announced that it has...
AstraZeneca’s Zoladex Receives NMPA Approval for Higher Dosage Form in Breast Cancer Treatment
AstraZeneca Inc., (AZ, NASDAQ: AZN), a UK-based pharmaceutical giant, has announced that it has received...
MicuRx Pharmaceuticals’ Antibiotic MRX-5 Completes Successful Phase I Clinical Trial in Australia
MicuRx Pharmaceuticals Inc. (SHA: 688373), a Sino-US pharmaceutical company, has announced the successful completion of...
Wantai Biological’s P85 Ab Detection Kit Receives NMPA Approval for Nasopharyngeal Carcinoma Screening
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a Chinese pharmaceutical company, announced last...
Chinese ADCs from Escugen, Hansoh, and MediLink Therapeutics Eye Breakthrough Designations in China
The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has indicated on...
GSK Commits USD 800 Million to New State-of-the-Art Manufacturing Facility in Pennsylvania
GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced a significant investment in...
ImmuneOnco Biopharmaceuticals Partners with Yangtze River Pharmaceutical to Boost Pipeline Development
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a biopharmaceutical company based in China, has entered...
LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control...
Zhuhai Beihai Biotech’s Beizary Receives FDA Clearance for Multiple Cancer Indications
Zhuhai Beihai Biotech Co., Ltd has announced that it has received marketing clearance from the...
BeiGene’s PD-1 Inhibitor Tevimbra Scores First US Prescription, Offers More Affordable Option
BeiGene Ltd, a leading China-based biotechnology company (NASDAQ: BGNE; HKG: 6160; SHA: 688235), has announced...
RemeGen’s Telitacicept Receives Priority Review Status from China’s CDE for gMG Treatment
RemeGen (HKG: 9995), a China-based pharmaceutical company, has announced that the Center for Drug Evaluation...
RemeGen’s Taitaxipu Receives CDE Acceptance for New Indication Application in China
RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) has announced that the Center for Drug Evaluation...
Shanghai MicroPort Initiates Pre-Marketing Clinical Study for Embolic Microspheres in Liver Cancer Treatment
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical technology company, has announced...
Chongqing Zhifei Biological’s Influenza Vaccine Application Accepted by China’s Drug Evaluation Center
On October 24, 2024, the Center for Drug Evaluation of the National Medical Products Administration...
TheDerma’s Series A+ Round to Fund R&D and Commercialization of AhR Targeted Drugs
TheDerma, a Shanghai-based pharmaceutical company, has announced the completion of a nearly CNY 100 million...